Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD)

https://www.galmedpharma.com

Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol™, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. Galmed is currently conducting the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol™ in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. More information about the ARREST Study may be found on ClinicalTrials.gov identifier: NCT02279524. *

	Start	2013-07-31 reorganised

	Region	Tel Aviv
	Country	Israel
	Street	16 Tiomkin Street
	City	6578317 Tel Aviv
	Tel	+972-3-693-8448
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Galmed Pharmaceuticals Ltd.. (4/3/18). "Press Release: Galmed Pharmaceuticals Announces Pricing of $6.0 Million Registered Direct Offering". Tel Aviv.

		Record changed: 2023-07-16

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]